GT方案与XT方案治疗复发转移性乳腺癌的临床观察  

Clinical observation of GT and XT regimen in the treatment of recurrent and metastatic breast cancer

作　　者：缪捷飞[1] 

机构地区：[1]南通大学附属医院肿瘤科,江苏南通226001

出　　处：《现代肿瘤医学》2015年第23期3442-3445,共4页Journal of Modern Oncology

摘　　要：目的：观察吉西他滨联合紫杉醇（GT）及卡培他滨联合多西他赛（XT）方案治疗复发转移性乳腺癌的临床疗效及毒副反应。方法：复发转移性乳腺癌患者36例,采用回顾性研究方法分为两组：GT组18人,第1天紫杉醇175mg/m^2静滴3小时,第1、8天吉西他滨1 000mg/m^2静滴30分钟,21天为一周期;XT组18人,第1天多西他赛75mg/m^2静滴1小时,第1～14天卡培他滨1 000mg/m^2口服Bid,周期同为21天。化疗期间观察患者化疗毒副反应,每两周期行影像学检查评价疗效。结果：GT组CR为11.1%,PR为38.9%,SD为27.8%,DCR为77.8%;XT组CR为5.6%,PR为44.4%,SD为22.2%,DCR为72.2%,两组对比无统计学差异（P〉0.05）。GT组中位TTP为8.7个月,XT组中位TTP为7.8个月,两者统计学上无差异（P〉0.05）。毒副反应方面GT组血小板减少发生率较XT组高,XT组手足综合征发生率高于GT组,其余各项无显著性差异（P〉0.05）。结论：GT方案与XT方案治疗复发转移性乳腺癌疗效确切,毒副反应能耐受。Objective： To study the clinical curative effect and adverse of gemcitabine plus taxol（ GT） and xeloda plus docetaxel（ XT） in recurrent and metastatic breast cancer. Methods： Using retrospective study,36 cases of recurrent and metastatic breast cancer were divided into two groups. The 18 patients in the GT group received the GT chemotherapy regimen（ taxol 175 mg / m^2 on the 1st day; gemcitabine 1 000 mg / m^2 on the 1st day and 8th day; and 21 days for a cycle. The 18 patients in the XT group received the chemotherapy regimen： docetaxel 75 mg / m^2 on the 1stday; Capecitabine orally 2 000 mg /（ m^2·d）,twice a day from the 1st day to 14 th day; and 21 days for a cycle. Results： In GT group,2 patients achieved complete response（ CR）,7 patients achieved partial remission（ PR）,5patients achieved stable disease（ SD）,and the response rate was about 77. 8%. In XT group,1 patient achieved complete response（ CR）,8 patients achieved partial remission（ PR）,4 patients achieved stable disease（ SD）,and the response rate was 72. 2%. There was no statistically significant differrence between two groups（ P〈0. 05）. The median TTP of GT group was 8. 7 months,while XT group median TTP was 7. 8 months,without any difference statistically. There was higher incidence of thrombocytopenia in GT group than XT group,and incidence of extremities syndrome in XT group was higher than GT group. Conclusion： The curative effect of GT and XT regimens in treating recurrent and metastatic breast cancer is obvious and the toxicities can be tolerated.

关 键 词：吉西他滨 紫杉醇 多西他赛 卡培他滨 复发转移性乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]